1. Clinical Overview
Levodropropizine is the levo-isomer of dropropizine, a non-opioid, peripherally-acting antitussive agent. It acts by inhibiting sensory neuropeptide release from C-fibers in the bronchial mucosa, thereby reducing cough reflex sensitivity. It is widely used in India for the symptomatic treatment of acute and chronic non-productive cough associated with various respiratory conditions, offering efficacy with a favorable safety profile and minimal central nervous system depression.
| Onset | Duration | Bioavailability |
|---|---|---|
| Approximately 30-45 minutes after oral administration. | Approximately 4-6 hours. | Approximately 70-80% after oral administration. |
2. Mechanism of Action
Levodropropizine selectively inhibits the release of sensory neuropeptides (such as Substance P) from unmyelinated C-fibers in the bronchial mucosa. This action reduces the sensitivity of the cough reflex arc at the peripheral level, without depressing the central cough center in the medulla oblongata.
3. Indications & Uses
- Symptomatic treatment of acute non-productive cough
- Symptomatic treatment of chronic non-productive cough associated with bronchitis, COPD, and other respiratory tract conditions
4. Dosage & Administration
Adult Dosage: 30 mg (5 ml) three times daily. Maximum: 180 mg/day.
Administration: For oral use only. Use the measuring cup or spoon provided. Can be taken with or without food. Shake the bottle well before each use. Maintain adequate hydration.
5. Side Effects
Common side effects may include:
- Mild drowsiness/somnolence
- Headache
- Dizziness
- Gastrointestinal discomfort (nausea, epigastric pain)
- Dry mouth
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| CNS Depressants (e.g., Alprazolam, Diazepam, Zolpidem, Phenobarbital) | Additive sedative effect, increased risk of drowsiness and impaired psychomotor performance. | Moderate |
| Alcohol | Potentiates CNS depressant effects, leading to increased sedation and dizziness. | Moderate |
| MAO Inhibitors (e.g., Phenelzine, Selegiline) | Theoretical risk of serotonin syndrome due to structural similarity to phenylpiperazine class. Avoid combination. | Major |
| Other Antitussives (e.g., Codeine, Dextromethorphan) | Increased antitussive effect, but also increased risk of side effects. Generally not recommended. | Moderate |
7. Patient Counselling
- DO take the exact dose as prescribed by your doctor.
- DO use the measuring device provided with the syrup.
- DO shake the bottle well before each use.
- DO inform your doctor if cough persists for more than 5 days or is accompanied by fever, rash, or persistent headache.
- DO NOT exceed the recommended dose.
- DO NOT use to suppress a productive cough (cough with phlegm).
- DO NOT drive or operate heavy machinery if you feel drowsy or dizzy.
- DO NOT consume alcohol while on this medication.
8. Toxicology & Storage
Overdose: Symptoms may include severe drowsiness, dizziness, nausea, vomiting, ataxia, and hypotension. In massive overdose, CNS depression and respiratory depression are theoretically possible, though less likely than with central antitussives.
Storage: Store at room temperature (15-30°C). Protect from light and moisture. Keep the bottle tightly closed. Keep out of reach and sight of children. Do not use after the expiry date printed on the label. Do not freeze.